




Review

New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review

Agni Kakouri ^{1,2,†} , Georgia Kanti ^{3,†}, Efthymios Kapantais ⁴, Alexandros Kokkinos ⁴, Leonidas Lanaras ⁴, Paul Farajian ⁴, Christos Galanakis ⁴, Georgios Georgantopoulos ⁴, Nikos F. Vlahos ⁵, George Mastorakos ⁶, Alexandra Bargiota ⁷ and Georgios Valsamakis ^{6,5,7,*}

- ¹ Athens Medical School, National and Kapodistrian University of Athens, 115 27 Athens, Greece; agni.kakouri@gmail.com
² Department of Ophthalmology & Visual Sciences, University of Illinois, Chicago, IL 60607, USA
³ Endocrinology and Diabetes Center, Athens General Hospital "G. Gennimatas", 115 27 Athens, Greece; g.kanti89@gmail.com
⁴ Hellenic Medical Association for Obesity, 115 27 Athens, Greece; ek@kapantais.gr (E.K.); rjd@otenet.gr (A.K.); leolanaras@gmail.com (L.L.); pfarajian@nutrimed.gr (P.F.); christos@myfamilydoctor.gr (C.G.); gg.psych.mail@gmail.com (G.G.)
⁵ Assisted Reproduction Unit, 2nd Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece; nfvlahos@gmail.com
⁶ Department of Endocrinology, Diabetes Mellitus and Metabolism, 2nd Department of Obstetrics and Gynecology, Aretaieion University Hospital, 115 28 Athens, Greece; mastorakg@gmail.com
⁷ University Department of Endocrinology and Metabolic Disorders, University Hospital of Larissa, University of Thessaly, 413 34 Larissa, Greece; abargio@uth.gr
* Correspondence: gedvalsamakis@yahoo.com
† These authors contributed equally to this work.



Citation: Kakouri, A.; Kanti, G.; Kapantais, E.; Kokkinos, A.; Lanaras, L.; Farajian, P.; Galanakis, C.; Georgantopoulos, G.; Vlahos, N.F.; Mastorakos, G.; et al. New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review. *Pharmaceuticals* **2021**, *14*, 869. <https://doi.org/10.3390/ph14090869>

Academic Editors: Amélie Pilar Rauter, Magdalena Kotańska, Małgorzata Szafarz and Monika Kubacka

Received: 27 July 2021

Accepted: 23 August 2021

Published: 28 August 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: The worldwide upward trend in obesity in adults and the increased incidence of overweight children suggests that the future risk of obesity-related illnesses will be increased. The existing anti-obesity drugs act either in the central nervous system (CNS) or in the peripheral tissues, controlling the appetite and metabolism. However, weight regain is a common homeostatic response; current anti-obesity medications show limited effectiveness in achieving long-term weight loss maintenance; in addition to being linked to various side effects. Combined anti-obesity medications (per os or injectable) target more than one of the molecular pathways involved in weight regulation, as well as structures in the CNS. In this systematic review, we conducted a search of PubMed and The ClinicalTrials.gov up to February 2021. We summarized the Food and Drug Administration (FDA)-approved medications, and we focused on the combined pharmacological treatments, related to the incretin hormones, currently in a clinical trial phase. We also assessed the mechanism of action and therapeutic utility of these novel hybrid peptides and potential interactions with other regulatory hormones that may have beneficial effects on obesity. As we improve our understanding of the pathophysiology of obesity, we hope to identify more novel treatment strategies.

Keywords: obesity; metabolism; anti-obesity combined medications; weight loss; incretins

1. Introduction

Obesity is a chronic metabolic disease, which can be defined as an excessive accumulation of body fat that leads to increased morbidity and mortality. Obesity has been shown to increase the risk of various medical conditions, such as diabetes mellitus type 2, cardiovascular disease, gallbladder disease, nonalcoholic fatty liver disease, several types of malignancies (i.e., in colon, endometrium, breast, esophagus, kidney), osteoarthritis, obstructive sleep apnea, and mental health problems, leading to increased morbidity and mortality [1]. The worldwide prevalence of obesity has nearly tripled between 1975 and 2016 and continues to rise at an alarming rate, rendering it a global pandemic [2]. It is

further estimated that up to 58% of the world's adult population could be overweight or obese by 2030 if the upward trends continue [3]. Obesity in adults is defined as a BMI of 30 kg/m² and above and overweight as a BMI between 25 and 29.9 kg/m² [4]. The pathophysiology of the disease is complex, and multiple factors are involved. Obesity arises from a chronic positive energy balance, which occurs when energy intake exceeds energy expenditure [5]. A better understanding of the body weight regulation mechanisms and human metabolism remains challenging and will help create effective prevention and treatment strategies against obesity. Currently approved anti-obesity medications have variable weight loss response and weight maintenance along with essential adverse effects, which render it unavoidable to discontinue the therapy [6]. Therefore, it is of great importance to explore new anti-obesity agents with combined actions on multiple levels in the pathophysiological mechanisms involved in the progression and maintenance of obesity.

2. Methods

A literature search was conducted using the database of PubMed and The [ClinicalTrials.gov](https://clinicaltrials.gov) from September 2020 up to February 2021. A query of clinical trials registries ([Clinicaltrials.gov](https://clinicaltrials.gov)) with the keyword “obesity” returned 9532 search results, which further contained 769 interventional completed studies with associated results using the keyword “interventional studies”. Out of the 769 studies, 492 were evaluating the effect of drugs either on obesity or in obese subjects. Out of 492, we evaluated only 56 clinical trials that provided available published results and were related to anti-obesity medications and incretin hormones.

3. Results

3.1. Approved Pharmacotherapy for Obesity

Over the last decade, five anti-obesity medications have received approval by the US Food & Drug Administration (FDA), providing promising anti-obesity therapeutic options (Table 1): orlistat, phentermine/topiramate, bupropion/naltrexone, liraglutide, and more recently, semaglutide [7–10]. The European Medicinal Agency (EMA) has approved only four of them: orlistat, bupropion/naltrexone, liraglutide, and semaglutide. In February 2020, Lorcaserin was withdrawn from the US market, as clinical trials showed an increased occurrence of malignancies [11]. Most of the FDA-approved anti-obesity medications are administered orally, except for liraglutide and semaglutide, which require daily injectable subcutaneous administration [12,13]. The existing anti-obesity drugs act either in the central nervous system (CNS) or in the peripheral tissues, controlling appetite and metabolism. The currently approved pharmacotherapies achieve a weight reduction of 5–15% [14].

Table 1. Weight loss medications FDA-approved in the USA.

Drug	Brand Name	Average Weight Loss in Treatment vs. Control Group	% of Subjects Losing > 5% of Initial Body Weight
Liraglutide	Saxenda	−7.7 kg vs. −3.3 kg [15]	64.7% [15]
Orlistat	Xenical, Alli	−6.8% vs. −3.8% from baseline [16]	64% [16]
Semaglutide	Wegovy	−14.9% vs. −2.4% change in body weight from baseline [17]	86.4% [17]
Naltrexone/Bupropion sustained release	Contrave	−9.3 ± 0.4 kg vs. −5.1 ± 0.6 kg [18]	66.4% [18]
Phentermine/Topiramate extended release	Qsymia	−10.5% vs. −1.8% change in body weight from baseline [19]	50% [19]
Lorcaserin ¹	Belviq	−5.8 ± 0.2 kg vs. −2.2 ± 0.1 kg [20]	47.5% [20]

¹ In February of 2020 Lorcaserin was withdrawn from the US market.

3.2. Orlistat

Orlistat acts by inhibiting pancreatic lipases, resulting in a reduction of intestinal fat digestion. It has been proved to be efficient in enabling weight loss, which was maintained up to 24 to 36 months after treatment [21]. In a 24-week double-blinded, placebo-controlled study, 120 mg of orlistat was administered three times daily. Bodyweight in the orlistat group was significantly reduced (6.8% from baseline) compared to the placebo group (3.8%). Furthermore, 64% of the subjects in the orlistat group achieved 5% weight loss in comparison with 39% in the placebo group [16]. Additionally, it has been shown to improve metabolic parameters, including the incidence of diabetes [22], blood pressure [23], and serum lipid levels [24]. The main adverse effects of orlistat are diarrhea, abdominal pain, and steatorrhea [25], while severe liver [26] and acute renal injury [27] have been reported only in a few cases. It may also lower the levels of fat-soluble vitamins [28]. The main contraindications reported are related to pregnancy, malabsorption syndrome, and cholestasis [29]. The drug is provided in 120 mg capsules and is recommended to be taken three times daily.

3.3. Phentermine/Topiramate

This combination drug aims at a greater efficacy with lower toxicity, as the two substances act synergistically. Phentermine is a sympathomimetic amine, which stimulates norepinephrine release, resulting in reduced appetite. Topiramate is an anticonvulsant, which was shown to have an anorexigenic action, thus inducing weight loss. The combination drug phentermine/topiramate was approved by the FDA in 2012 in a recommended dose of 7.5 mg phentermine/46 mg topiramate once daily [30]. The approval was based on three clinical trials: EQUIP [31], CONQUER [32], and SEQUEL [19]. In the CONQUER study, 75% of participants exhibited a reduction in body weight of >5% of baseline, as well as improvement in blood pressure, lipid levels, fasting glucose, and a lower waist circumference. In these trials, the most common adverse reactions reported were constipation, paresthesia, and dry mouth. The combination drug is contraindicated in pregnancy and uncontrolled hypertension [33].

3.4. Bupropion/Naltrexone

Bupropion/naltrexone is a combination drug, which consists of two already approved centrally acting medications. It acts by reducing appetite through the activation of POMC neurons in the arcuate nucleus. Bupropion is a dopamine and norepinephrine-reuptake inhibitor, used as an antidepressant and for smoking cessation [34]. Naltrexone is an opioid receptor antagonist, prescribed for alcohol or opiate dependence [35]. The combination of bupropion/naltrexone was approved by the FDA in 2014 [36]. It has been shown to reduce weight by approximately 4–5% compared to placebo [37]. In a 56-week placebo-controlled trial, weight loss was $9.3 \pm 0.4\%$ in the bupropion/naltrexone group compared to $5.1 \pm 0.6\%$ in the placebo group. Significantly more participants (66.4%) in the bupropion/naltrexone group lost >5% of their body weight at week 56 compared to 42.5% in the control group [18]. Regarding the adverse effects, nausea, headache, and constipation were most frequently reported [38]. Pregnancy, seizures, anorexia/bulimia, alcohol withdrawal, and/or the use of monoamine oxidase inhibitors within 2 weeks of drug initiation are the major reported contraindications [39]. The recommended dose is 16 mg naltrexone/180 mg bupropion twice daily.

3.5. Liraglutide

Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is administered subcutaneously (3 mg once daily) [40]. GLP-1 agonists activate GLP-1 receptors in the central nervous system. They stimulate the POMC/CART neurons, which have anorexigenic action, and they inhibit orexigenic neurons, which express neuropeptide Y [41]. Moreover, they improve glucose-dependent insulin release, suppress glucagon release, and decrease the rate of gastric emptying [42,43]. In the Satiety and Clinical Adiposity-Liraglutide

Evidence in non-diabetic and diabetic people (SCALE) study, subjects were enrolled in a 56-week, randomized, double-blind, placebo-controlled, multicenter trial in which individuals with obesity received liraglutide 3.0 mg or placebo in combination with intensive behavioral therapy. At 56 weeks, the mean weight loss in the placebo group was 4.0%, while in the treatment group, it was 7.5%. More than 5% weight loss was achieved in 61.5% of subjects in the liraglutide group compared to 38.8% in placebo [44]. In the XENSOR study, weight reduction was 7.7 kg, significantly greater compared to 3.3 kg with orlistat. A total of 64.7% of patients lost >5% of their baseline weight compared with orlistat, of which only 27.4% achieved this endpoint [15]. The most common side effect associated with GLP-1 therapy is short-term nausea. Other common adverse effects include hypoglycemia, diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, and increased levels of lipase [45]. The main contraindications reported are related to pregnancy, multiple endocrine neoplasia 2 syndrome, history of medullary thyroid cancer and acute or chronic pancreatitis [46]. Attenuating hyperglycemia during meals is particularly beneficial in patients with hyperglycemia or diagnosed diabetes [47].

3.6. Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist. Semaglutide mimics the effects of GLP-1 by increasing satiety, reducing appetite for food, prospective food consumption, and energy intake [41]. Semaglutide decreases blood glucose by increasing insulin secretion and decreasing glucagon secretion, both in a glucose-dependent manner [12]. A 68-week randomized, double-blind, placebo-controlled trial investigated the effects of once-weekly subcutaneous semaglutide injection, at a dose of 2.4 mg, in 1961 obese patients. Semaglutide resulted in a 14.9% mean weight reduction from baseline compared with a 2.4% reduction in the placebo group (95% CI −13.4 to −11.5; $p < 0.001$). A total of 86.4% of participants in the treatment group achieved weight reductions of 5% or more compared to 31.5% in the placebo group. Participants in the semaglutide group had improved cardiometabolic risk factors and fewer food cravings. The most frequent side effects were dose-related nausea and diarrhea [17]. Semaglutide should not be used in patients with history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as it increases the risk for thyroid c-cell carcinoma [48]. Contraindications are similar to liraglutide and the rest of the GLP-1 agonists since they have equal mechanisms of action. In another randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial, 957 individuals were enrolled. The mean weight loss for the placebo group was −2.3% compared to −6% (0.05 mg), −8.6% (0.1 mg), −11.6% (0.2 mg), −11.2% (0.3 mg), and −13.8% (0.4 mg) for the semaglutide subcutaneous groups. Weight loss of more than 10% occurred in 37–65% of participants receiving 0.1 mg or more of semaglutide compared to 10% in the placebo group ($p < 0.001$). Furthermore, the liraglutide group (3.0 mg subcutaneous) had a 7.8% reduction in body weight significantly less than the 11–14% reduction with semaglutide doses of 0.2 mg or more. Consistent improvements in glucose and cardiac parameters such as lipids and high-sensitivity C-reactive protein were seen for the semaglutide group versus placebo [49]. The PIONEER trial program is evaluating the efficacy and safety of oral semaglutide in diabetes type II. Patients were randomly assigned to oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. All doses of oral semaglutide resulted in a reduction in HbA_{1C}. The 14 mg semaglutide provided statistically significant higher reductions in body weight compared to placebo at 26 weeks. In another part of the PIONEER trial, oral semaglutide (dose-escalated to 14 mg) was compared to liraglutide (dose-escalated to 1.8 mg) for 52 weeks. The results showed that HbA_{1C} was significantly decreased in the semaglutide group compared to the liraglutide group. Similarly, weight loss was increased in the semaglutide group compared to the liraglutide with an estimated treatment difference of −1.3 kg ($p < 0.001$) and −3.3 kg for the placebo group. Consequently, oral semaglutide may be a breakthrough treatment for patients with diabetes type II or obesity who are not inclined to have an injectable therapy [50–55].

3.7. Pharmacotherapy for Obesity under Investigation

Recent research has suggested that the therapeutic implications of incretin hormones as combination agents in obesity, such as GLP-1 plus GIP, GLP-1 plus glucagon, GLP-1 plus GIP plus glucagon receptor agonists, GLP-1 plus amylin analogue, may have promising potential for weight loss and weight maintenance.

Biology of Incretins

Incretins are peptide hormones secreted by the gastrointestinal tract after nutrient intake. The two major incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide or gastric inhibitory polypeptide (GIP) [56]. GLP-1 is a 30-amino acid peptide hormone, secreted from the intestinal endocrine L-cells, mainly located in the ileum but also in the duodenum, colon, and rectum. This hormone is “meal-related”, meaning that during the fasting state, plasma concentrations are very low, while during meals, especially those rich in fats and carbohydrates, GLP-1 secretion is rapidly enhanced [57]. GIP is a 42-amino-acid peptide which is secreted from K-cells; specific endocrine cells located on the duodenum and proximal jejunum [58]. GIP is secreted in response to the ingestion of nutrients such as fat and carbohydrates [40]. Dipeptidyl peptidase 4 (DPP-4) enzyme is responsible for the rapid degradation of GLP-1 and GIP to inactive metabolites. DPP-4 is a serine protease that specifically cleaves dipeptides from the amino terminus of proteins that contain an alanine or proline residue in the second position [59]. The actions of GIP and GLP-1 are mediated by the engagement of G-protein-coupled receptors expressed on pancreatic α - and β -cells and in various tissues, including the gastrointestinal tract, kidneys, central nervous system, heart, and lungs. Stimulation of the incretin receptors activates adenylyl cyclase, which increases cyclic adenosine monophosphate c-AMP levels and protein kinase A activation. This leads to insulin secretion in a glucose-dependent manner [60]. GLP-1 results in enhanced insulin secretion [42] and GIP stimulates insulin secretion by β -pancreatic cells in a glucose-dependent manner [43]. GLP-1 suppresses glucagon secretion from pancreatic α -cells only during states of hyperglycemia and euglycemia which reduces hepatic glucose production. During hypoglycemia, glucagon release is fully preserved, even in the presence of pharmacological concentrations of GLP-1. Interestingly, insulinotropic but not glucagon static effects of GLP-1 are significantly reduced in patients with diabetes [57]. On the contrary, GIP enhances postprandial glucagon response, stimulates glucagon secretion from pancreatic α -cells during a state of hypoglycemia or euglycemia but not during hyperglycemia and stimulates glucagon secretion. The fundamental effect associated with these hormones is called the incretin effect. Oral glucose leads to amplified insulin secretion by the pancreatic β -cells compared to the intravenous glucose administration, despite inducing similar levels of glycemia, in healthy individuals [56]. This phenomenon is explained by the fact that oral glucose leads to the release of incretin hormones from the gastrointestinal tract, while intravenous glucose does not. Furthermore, GLP-1 reduces gastrointestinal secretion by exhibiting an inhibitory effect on pentagastrin and meal-stimulated gastric acid secretion [43]. It also diminishes gastrointestinal motility, which contributes to the normalization of blood glucose levels in type II diabetes mellitus after exogenous GLP-1 administration and promotes satiety by ensuing reduction of food intake [44]. Additionally, GLP-1 has a direct effect on hypothalamic neurons and regulates energy homeostasis and food consumption [43]. GIP has been associated with increased blood flow to adipose tissue and intestines as well as with enhanced triacyl glyceride deposition in the adipose. The anabolic effects of GIP include stimulation of fatty acid synthesis, re-esterification, incorporation of fatty acids into triglycerides stimulated by insulin, lipoprotein lipase synthesis, and lowering of glucagon-stimulated lipolysis [56].

3.8. GIP/GLP-1 Receptor Agonists

A dual non-biased agonist of GIP receptor and GLP-1 receptor, tirzepatide (also known as LY3298176), has been developed for a once-weekly injectable administration [61]. The combination of insulinotropic actions of GIP with the favorable cardiovascular out-

comes and weight reduction of GLP-1 may offer superior glycemic control in the treatment of diabetes mellitus type II [62]. Compared to a selective GLP-1 receptor agonist, the synergistic action of GIP combined with GLP-1 shows more effective weight loss and reduction in food intake with increased energy expenditure in genetic mouse models with diet-induced obesity [61]. Increasing doses of tirzepatide (2.5–15 mg once weekly subcutaneous) over a period of 12 weeks was compared to placebo in 111 patients. Tirzepatide dose-dependently significantly reduced HbA_{1C}. Tirzepatide also reduced weight by 5.7 kg from baseline in subjects receiving 15 mg compared to 0.5 kg in the placebo group [62]. In another 26-week phase 2b clinical trial, 316 subjects were enrolled and assigned randomly in three groups: the tirzepatide group, the dulaglutide group (a GLP-1 receptor agonist), and the placebo group. Tirzepatide, like dulaglutide, reduces fasting, postprandial plasma glucose and HbA_{1C}. Bodyweight was reduced with tirzepatide (−0.9, −4.8, −8.7, and −11.3 kg for 1, 5, 10, and 15 mg, respectively) compared to a 2.7 kg reduction with dulaglutide and 0.4 kg weight loss in the placebo group. A total of 14–71% of subjects treated with tirzepatide achieved at least 5% weight reduction and 6–39% achieved the target of at least 10% weight reduction [63]. The most frequent side effects reported with LY3298176 were dose-dependent gastrointestinal symptoms, such as vomiting, nausea, decreased appetite, diarrhea, and abdominal distension [62,64]. The SURPASS phase 3 trials aim to assess the safety and efficacy of escalating doses of tirzepatide starting from 2.5 mg weekly until the maintenance dose of 15 mg [65]. The SURPASS-2 40-week trial compared increasing doses of tirzepatide (once weekly) versus semaglutide injections in 1879 patients. A total of 86% of the patients achieved HbA_{1C} reduction below 7% compared to 79% treated with semaglutide. Moreover, the average weight loss with tirzepatide was 1.9 kg and 5.5 kg, additional to what semaglutide achieved, for the 5 mg and 15 mg, respectively [66]. In clinicaltrials.gov, trials utilizing these dual agonists are still ongoing; however, the results of the studies are unpublished at the time of writing.

3.9. GLP-1/Glucagon Receptor Agonists

Oxyntomodulin is a 37-amino acid peptide hormone produced by enteroendocrine L-cells of the gastrointestinal tract after enzymatic processing [67]. Oxyntomodulin is released post-prandially in response to nutrients, such as carbohydrates, lipids, and proteins. Oxyntomodulin is subject to proteolytic cleavage by dipeptidyl-peptidase-4 and fast renal clearance. Oxyntomodulin's main role is to suppress appetite by acting as an agonist of both GLP-1 and glucagon receptors and improve glucose metabolism [68]. The combination of lipolytic and thermogenic actions of glucagon with the anorectic and insulinotropic actions of GLP-1 is crucial for the targeted management of obesity [69]. Oxyntomodulin reduces food intake and enhances energy expenditure by activating both GLP-1 receptors and glucagon receptors. In a 4-week study, obese and overweight subjects were given oxyntomodulin subcutaneous injection (400 nmol) or placebo three times daily 30 min pre-prandial. At the end of the study, it was reported that subjects in the treatment group had an average weight loss of 2.4 ± 0.4 kg compared to the control group, which had an average weight reduction of 0.5 ± 0.6 kg. Moreover, energy intake was lower on day 2 and day 29 compared to day 1, suggesting that weight loss could be maintained over time [70]. Consequently, clinical experience with oxyntomodulin showed promising evidence that a three-times daily subcutaneous administration in 4 weeks provides vigorous weight loss to obese individuals [71]. Synthetic oxyntomodulin with optimal balancing of GLP-1 and glucagon receptor activities produces a significant and sustained increase in energy expenditure, compared to the gut hormone, as discussed by Scott. et al. [72]. Oxyntomodulin has been reported to enhance insulin secretion in short-term clinical studies in obese people with or without diabetes mellitus type II [73]. Another 6-week experimental study on diet-induced obese diabetic monkeys showed that a combination of GLP-1 receptor agonist and glucagon receptor agonist significantly reduced body weight by $6.6 \pm 0.9\%$. However, glucagon receptor agonist alone had no effect on body weight while GLP-1 receptor agonist lowered body weight by $3.8 \pm 0.9\%$ and energy intake by 18% [74]. Few incidences of

acute pancreatitis have been reported during treatment with GLP-1R agonists apart from gastrointestinal side effects [75]. Moreover, glucagon and GLP-1 have positive inotropic and chronotropic action on the heart with mild decreases in LDL-C and triglycerides levels [76,77]. Recent clinical studies showed that cotadutide, a dual receptor GLP-1/Glucagon agonist, improves glycemic control and promotes weight reduction. More specifically, in a 49-day placebo-controlled study, 65 obese subjects were given once-daily subcutaneous cotadutide. A total of 42% of subjects achieved an over 5% reduction in body weight compared to 8% in the control group. The bodyweight reduction was 3.41% from baseline in the cotadutide group versus 0.08% in the control group, suggesting promising results for the treatment of obesity [78].

3.10. GLP-1 Receptor Agonist/Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitor

Under physiologic conditions, up to 180 g of glucose is filtered by the renal glomerulus daily and all of it is subsequently reabsorbed in the proximal convoluted tubule. This tubular glucose reabsorption is affected by the combined action of two sodium-dependent glucose cotransporter (SGLT) proteins. Once glucose has been reabsorbed into the tubular epithelial cells, it diffuses into the interstitial space across specific facilitative glucose transporters (GLUTs) [79]. SGLT2 inhibitors block the pathway of SGLT2 glucose reabsorption in the proximal convoluted tubule, resulting in profound glucosuria and natriuresis [80]. SGLT2 inhibitors are used in the treatment of type II diabetes, while they exhibit cardioprotective and anti-atherosclerotic effects [80,81]. The combined action of SGLT2 inhibitors to cause caloric loss via glucosuria, with the GLP-1 receptor agonist to reduce appetite and caloric intake, presumably leads to additive effects on weight reduction. Moreover, GLP-1 receptor agonists and SGLT2 reduce total body weight by lowering the visceral fat via increasing urinary glucose excretion and subcutaneous adipose tissue volume [82]. Consequently, SGLT2 inhibitors are successful for the treatment of diabetes mellitus type II, and they also seem to reduce total body weight. In a randomized, double-blind placebo-controlled trial, 126 obese patients were randomly assigned to the placebo group or licogliflozin group, a dual SGLT1/2 inhibitor (LIK066), once daily. At the endpoint of 12 weeks, the percentage change in body weight from baseline was -1.86 , -2.84 , -3.41 , and -3.80% in licogliflozin 2.5, 10, 25, and 50 mg dose groups, respectively, compared to the control group, which was 0.11. The proportion of responders with a $\geq 3\%$ reduction in body weight in the licogliflozin 2.5, 10, 25, and 50 mg dose groups were 15.8%, 55.6%, 50.0%, and 56.7%, respectively, versus placebo 7.1%; $p \leq 0.002$ for all except the 2.5 mg once-daily group ($p = 0.39$). Licogliflozin also promoted a dose-dependent reduction in uric acid levels and HbA_{1c}. Licogliflozin was well tolerated, and no safety issues raised [83]. A recent clinical trial studies the effects of combined dapagliflozin with GLP-1 analogue exenatide. The results demonstrated a mean weight loss of 4.5 kg over a period of 24 weeks that increased to 5.7 kg [84] over a period of 52 weeks, suggesting promising effects on sustained reductions in body weight [85]. Another 28-week clinical trial evaluated the combination of exenatide plus dapagliflozin once daily versus exenatide or dapagliflozin alone. The dual combination led to significant weight loss, HbA_{1c}, and blood pressure reduction with no unexpected side effects. The most usual adverse effects reported with dapagliflozin in clinical trials were female genital mycotic infections, urinary tract infections, and nasopharyngitis [86]. The weight change was -3.55 kg in the combination group versus -1.56 in the exenatide group and -2.22 in the dapagliflozin group. Weight loss of 5% or more was achieved in 33% of the dual combination group compared to 14% in the exenatide and 20% in the dapagliflozin group [87]. The safety of canagliflozin, when used in combination with a GLP-1 agonist, was evaluated in the CANVAS study in patients with diabetes type II. The most common adverse events reported were diarrhea, injection-site erythema, nausea, urinary tract infections, genital mycotic infections, and osmotic diuresis-related effects [88].

3.11. GLP-1 Receptor Agonist/Amylin Analogue

Cagrilintide is a novel long-acting acylated amylin analogue that is combined with semaglutide and leads to greater weight loss compared to semaglutide monotherapy [89]. Amylin is a 37-amino acid polypeptide that is co-released with insulin from β -pancreatic cells and is involved in delaying gastric emptying [90]. Cagrilintide has agonistic properties on amylin and calcitonin receptors. Recent evidence shows that amylin is expressed in certain central nervous system pathways that are involved in metabolism and energy regulation, such as the hypothalamus [91]. In a recent randomized, placebo-controlled 20-week study, a once-weekly subcutaneous dose of cagrilintide 4.5 mg therapy combined with subcutaneous semaglutide 2.4 mg led to 15.4% of weight loss compared with matched placebo that was 8%, without any lifestyle modifications. A total of 96 individuals were enrolled in the study and the results showed a 15.7% bodyweight reduction from baseline with 1.2 mg cagrilintide and 17.1% reduction with 2.4 mg cagrilintide compared to placebo (both in combination with semaglutide 2.4 mg). The most common side effect was gastrointestinal disorder, with nausea being the most frequently reported [92].

3.12. GLP-1/GIP/Glucagon Receptor Agonists

This new triagonist has been shown to decrease plasma glucose levels and to promote weight loss in obese rodents with higher metabolic benefits compared to diagonists such as GLP-1 and glucagon. Glucagon increases energy expenditure, and when combined with GLP-1, which acts as an appetite suppressant, results in a net loss of body weight. GIP receptor agonism and GLP-1 receptor agonism limit the hyperglycemia caused by glucagon and improves insulin sensitivity [42]. Consequently, the triagonist may improve the overall weight loss and metabolic profile of the patients. In an animal study by Hofmann S. et al., it was demonstrated that male and female mice with the same body fat mass had lower body weight, fat mass, and diminished food intake after being treated with injectable GLP-1/GIP/glucagon triple agonist. In addition, dyslipidemia was also improved in both female and male mice and diet-induced steatohepatitis was reversed in the female mice [93]. Another study in rodent models further showed that the triagonist considerably improved glucose tolerance and insulin sensitivity, and lowered food intake [94]. It also presented that mice had reduced body weight by 26.6% compared to GLP-1/GIP receptor agonist, which decreased weight by 15.7% after 20 days of treatment. Furthermore, the triagonist was reported to lessen the plasma cholesterol concentration to a higher extent compared with the GLP-1/GIP dual agonist. In a more recent study, Kannt A. et al. showed that mice that were placed on a specific diet, which led to non-alcoholic steatohepatitis and liver fibrosis, for 36 weeks lost 8% to 9% of their diet-induced body weight after 8 weeks of treatment with the combination of glucagon, GLP-1, and GIP. The main reason for the weight loss was the initial decrease in food consumption during the first week of the trial, which remained stable across the study period. Moreover, the triagonist led to an improvement in steatohepatitis, which was confirmed by a biopsy, of the diet-induced obese mice [95]. Based on the promising results of the animal studies, few GLP-1/GIP/Glucagon receptor agonists are currently under phase 1 clinical trial investigation. These are the Hanmi Pharmaceuticals with the HM15211 compound and the Novo Nordisk/Marcadia with MAR423. Results regarding their safety and efficacy remain to be published.

3.13. GLP-1 Receptor Agonist/Oxyntomodulin/Peptide YY

GLP-1, peptide YY, and oxyntomodulin are all secreted by the L-cells in the small intestine and colon. Peptide YY (PYY) is a 36-amino acid gastrointestinal hormone which exhibits an anorexic effect via the neuropeptide Y₁, Y₂ receptors, in the arcuate nucleus [86]. Studies showed that infusion of the PYY in healthy volunteers induces a 33% reduction in caloric intake over 24 h [96]. Other roles of PYY include delaying gastric emptying, altering colonic motility, and reducing postprandial insulin secretion [88]. Roux-en-Y gastric bypass increases the levels of GLP-1 [89], PYY [89], and oxyntomodulin post-prandially [97]. Moreover, Roux-en-Y gastric bypass decreases the levels of GIP, as it prevents the nutrient

exposure to the duodenum and jejunum the sites where GIP is secreted in response to nutrients [98]. This novel triple combination, given by subcutaneous infusion, was studied in a recent single-blinded clinical study for 4 weeks, in 15 obese patients with diabetes or prediabetes [99]. Study outcomes showed that weight was reduced by 4.4 kg in the treatment group (−4.0% percentage change from baseline) compared to the placebo group, in which weight was reduced by 2.5 kg (−2% percentage change from baseline). The triple combination infusion also improved glycemia and reduced glucose variability. The infusion did not have any significant side effects, apart from mild erythema around the infusion site [92]. Introductory results for the above combination were provided by the study of Schmidt et al. The study showed that the co-infusion of GLP-1 and PYY3-36 reduces energy intake compared with placebo (−30.4 ± 6.5%) and enhanced the satiety effect following a meal, demonstrating a synergistic effect [100].

4. Discussion

Given the upward trend in the worldwide obesity prevalence and its numerous health and socioeconomic consequences, the need for combating obesity remains crucial. The existing treatment options include alterations in lifestyle and diet, as well as surgical and pharmacological approaches, with mechanisms that are not clearly understood and result in a variety of side effects. Besides the adverse effects, weight regain is a common homeostatic response after excessive weight loss and current anti-obesity medications show limited effectiveness in achieving long-term weight loss maintenance [101]. Consequently, the aim of treatment for overweight individuals is long-term weight reduction with maintenance, management of co-morbidities, improvement of the metabolic and cardiovascular profile and increase in the life expectancy [102]. A weight loss of 5% of body weight has been shown to be beneficial, while pharmacotherapy in combination with behavioral amendments achieving weight loss of 5–10% is considered satisfactory [96]. It is essential that drug therapy is used combined with a healthy diet, physical activity, and behavior alteration. The decision to initiate pharmacotherapy should be individualized and made after consideration of the risks and benefits when the individual's BMI is over 30 kg/m² or over 27 kg/m² with an obesity-related disease [14]. Currently, bariatric surgery is the most effective therapeutic intervention for obesity but is approved only for the late stages of the disease. Weight reduction is mainly based on the hormonal alterations that lead to overall metabolic improvements. GLP-1 and PYY levels significantly increase after Roux-en-Y bypass due to increased deposition of large nutrient load to the distal gut. Levels of leptin, estrogen, and ghrelin decrease, while adiponectin, insulin, and cholecystokinin increase. GIP levels have inconsistent elevations or no change. This elevation in incretin hormones leads to increased satiety and improved insulin sensitivity. However, bariatric surgery is associated with various side effects due to hormonal imbalance, such as bone loss, vitamin deficiencies [103], and anatomical complications such as dumping syndrome, peritonitis, and superior mesenteric vein thrombosis [104]. Therefore, there is an urgency for less invasive treatments with a similar efficacy. Gut hormones, GLP-1, GIP, oxyntomodulin, and peptide YY lead to appetite suppression and reduced food intake, as well as increased energy expenditure [105]. Through their actions, the overall weight loss and metabolic profile of the patients may be improved. Their key role in weight regulation and metabolism makes them a promising potential target for pharmacotherapy. The development of combined anti-obesity medications (per os or injectable) that target more than one of these redundant molecular pathways, involved in weight regulation, as well as structures in CNS such as the habenula is a novel approach that may increase efficacy and improve tolerability. Combination pharmacotherapies may also achieve greater weight loss than monotherapies, via additive or synergistic effects, without causing major side effects. Data from recent clinical trials on GLP-1, GIP, glucagon receptor agonists, amylin analogues show positive results regarding weight loss (Table 2). Further clinical trials are required in order to strengthen whether these dual GLP-1/glucagon agonists are superior to GLP-1 analogues. Maintenance remains challenging and requires lifestyle and diet changes

in combination with pharmacotherapy. However, the synergistic effect of combination agents is proven to be beneficial towards that goal. Moreover, triagonist compounds have already shown positive results in animal studies regarding nonalcoholic steatohepatitis and cholesterol-lowering effects.

Table 2. Weight loss combined medications under investigation.

Drug	Average Weight Loss in Treatment Group versus Placebo Group	Side Effects	Clinical Trial Time Frame
GIP/GLP-1 Receptor Agonist [63]	−0.9 to −11.3 kg vs. −0.4 kg	Nausea, vomiting, diarrhea, decreased appetite	26 weeks
GLP-1/Glucagon Receptor Agonists [71]	−2.4 ± 0.4 kg vs. −0.5 ± 0.6 kg	Mild nausea, discomfort at injection site	4 weeks
SGLT2/GLP-1 Receptor Agonists [87]	−3.55 (−4.12 to −2.99) vs. −1.56 (−2.13 to −0.98) or −2.22 (−2.78 to −1.66)	Diarrhea, nausea, injection site nodules, urinary tract infections	28 weeks
GLP-1 Receptor Agonist/Amylin Analogue [92]	−15.9 (SE 1.40) vs. −7.8 (SE 2.2)	Nausea (most common), vomiting, dyspepsia, decreased appetite	20 weeks
GLP-1/GIP/Glucagon Receptor Agonists [93] ¹	−26.6% vs. −15.7%	-	20 days

¹ Animal rodent/mice studies. SE: standard error.

5. Conclusions

In the field of obesity, combination therapies are currently under investigation. The existing anti-obesity medications have failed to provide sustainable weight loss over time. Moreover, various drugs that have reached advanced stages of clinical trials were withdrawn later due to safety issues. The approval of additional pharmacological therapies that aim to promote sustained weight loss in the obese population is mandatory. Intensive behavioral changes are also required in combination with pharmacotherapy, dietary changes, and exercise to produce the desired weight loss. The future of optimized anti-obesity pharmacotherapy is targeted towards weight maintenance and individualized combination therapy based on the metabolic profile of the person.

Author Contributions: G.V. designed and supervised the study. A.K. (Agni Kakouri) and G.K. wrote the manuscript, contributed equally to the study design, created the initial draft of the manuscript and reviewed the literature. G.V. critically revised the manuscript. A.K. (Alexandros Kokkinos), C.G., E.K., G.G., L.L. and P.F. revised the manuscript. G.M., A.B. and N.F.V. revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The Hellenic Medical Association for Obesity funded the review.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing not applicable.

Acknowledgments: The review was under the auspices of Hellenic Medical Association for Obesity. We thank the Hellenic Medical Association for Obesity for providing funding for this review.

Conflicts of Interest: The authors declare no conflict of interest. This article is based on previously conducted studies and does not contain any studies with human subjects or animals performed by the authors.

References

1. Finer, N. Medical Consequences of Obesity. *Medicine* **2015**, *43*, 88–93. [[CrossRef](#)]
2. Abarca-Gómez, L.; Abdeen, Z.A.; Hamid, Z.A.; Abu-Rmeileh, N.M.; Acosta-Cazares, B.; Acuin, C.; Adams, R.J.; Aekplakorn, W.; Afsana, K.; Aguilar-Salinas, C.A.; et al. Worldwide Trends in Body-Mass Index, Underweight, Overweight, and Obesity from 1975 to 2016: A Pooled Analysis of 2416 Population-Based Measurement Studies in 128.9 Million Children, Adolescents, and Adults. *Lancet* **2017**, *390*, 2627–2642. [[CrossRef](#)]
3. Kelly, T.; Yang, W.; Chen, C.-S.; Reynolds, K.; He, J. Global Burden of Obesity in 2005 and Projections to 2030. *Int. J. Obes.* **2008**, *32*, 1431–1437. [[CrossRef](#)]
4. WHO. *Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation*; Technical Report; World Health Organisation: Geneva, Switzerland, 2000; pp. 1–253.
5. Hill, J.O. Understanding and Addressing the Epidemic of Obesity: An Energy Balance Perspective. *Endocr. Rev.* **2006**, *27*, 750–761. [[CrossRef](#)]
6. Kang, J.G.; Park, C.-Y. Anti-Obesity Drugs: A Review about Their Effects and Safety. *Diabetes Metab. J.* **2012**, *36*, 13. [[CrossRef](#)]
7. Halpern, B.; Mancini, M.C. Safety Assessment of Combination Therapies in the Treatment of Obesity: Focus on Naltrexone/Bupropion Extended Release and Phentermine-Topiramate Extended Release. *Expert Opin. Drug Saf.* **2017**, *16*, 27–39. [[CrossRef](#)]
8. Halpern, B.; Halpern, A. Safety Assessment of FDA-Approved (Orlistat and Lorcaserin) Anti-Obesity Medications. *Expert Opin. Drug Saf.* **2015**, *14*, 305–315. [[CrossRef](#)]
9. Nuffer, W.A.; Trujillo, J.M. Liraglutide: A New Option for the Treatment of Obesity. *Pharmacotherapy* **2015**, *35*, 926–934. [[CrossRef](#)] [[PubMed](#)]
10. Lewis, A.L.; McEntee, N.; Holland, J.; Patel, A. Development and Approval of Rybelsus (Oral Semaglutide): Ushering in a New Era in Peptide Delivery. *Drug Deliv. Transl. Res.* **2021**. [[CrossRef](#)]
11. Sharretts, J.; Galescu, O.; Gomatam, S.; Andraca-Carrera, E.; Hampf, C.; Yanoff, L. Cancer Risk Associated with Lorcaserin—The FDA’s Review of the CAMELLIA-TIMI 61 Trial. *N. Engl. J. Med.* **2020**, *383*, 1000–1002. [[CrossRef](#)]
12. Anderson, S.L.; Beutel, T.R.; Trujillo, J.M. Oral Semaglutide in Type 2 Diabetes. *J. Diabetes Complicat.* **2020**, *34*, 107520. [[CrossRef](#)]
13. Srivastava, G.; Apovian, C. Future Pharmacotherapy for Obesity: New Anti-Obesity Drugs on the Horizon. *Curr. Obes. Rep.* **2018**, *7*, 147–161. [[CrossRef](#)]
14. Apovian, C.M.; Garvey, W.T.; Ryan, D.H. Challenging Obesity: Patient, Provider, and Expert Perspectives on the Roles of Available and Emerging Nonsurgical Therapies. *Obes. Silver Spring* **2015**, *23* (Suppl. 2), S1–S26. [[CrossRef](#)] [[PubMed](#)]
15. Gorgojo-Martínez, J.J.; Basagoiti-Carreño, B.; Sanz-Velasco, A.; Serrano-Moreno, C.; Almodóvar-Ruiz, F. Effectiveness and Tolerability of Orlistat and Liraglutide in Patients with Obesity in a Real-World Setting: The XENSOR Study. *Int. J. Clin. Pract.* **2019**, *73*, e13399. [[CrossRef](#)]
16. Muls, E.; Kolanowski, J.; Scheen, A.; Van Gaal, L.; ObelHyx Study Group. The Effects of Orlistat on Weight and on Serum Lipids in Obese Patients with Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled, Multicentre Study. *Int. J. Obes.* **2001**, *25*, 1713–1721. [[CrossRef](#)]
17. Wilding, J.P.H.; Batterham, R.L.; Calanna, S.; Davies, M.; Van Gaal, L.F.; Lingvay, I.; McGowan, B.M.; Rosenstock, J.; Tran, M.T.D.; Wadden, T.A.; et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N. Engl. J. Med.* **2021**, *384*, 989. [[CrossRef](#)]
18. Wadden, T.A.; Foreyt, J.P.; Foster, G.D.; Hill, J.O.; Klein, S.; O’Neil, P.M.; Perri, M.G.; Pi-Sunyer, F.X.; Rock, C.L.; Erickson, J.S.; et al. Weight Loss with Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial. *Obes. Silver Spring* **2011**, *19*, 110–120. [[CrossRef](#)] [[PubMed](#)]
19. Garvey, W.T.; Ryan, D.H.; Look, M.; Gadde, K.M.; Allison, D.B.; Peterson, C.A.; Schwiers, M.; Day, W.W.; Bowden, C.H. Two-Year Sustained Weight Loss and Metabolic Benefits with Controlled-Release Phentermine/Topiramate in Obese and Overweight Adults (SEQUEL): A Randomized, Placebo-Controlled, Phase 3 Extension Study. *Am. J. Clin. Nutr.* **2011**, *95*, 297–308. [[CrossRef](#)]
20. Smith, S.R.; Weissman, N.J.; Anderson, C.M.; Sanchez, M.; Chuang, E.; Stubbe, S.; Bays, H.; Shanahan, W.R.; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management. *N. Engl. J. Med.* **2010**, *363*, 245–256. [[CrossRef](#)] [[PubMed](#)]
21. Leblanc, E.S.; O’Connor, E.; Whitlock, E.P.; Patnode, C.D.; Kapka, T. Effectiveness of Primary Care-Relevant Treatments for Obesity in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force. *Ann. Intern. Med.* **2011**, *155*, 434–447. [[CrossRef](#)]
22. Torgerson, J.S.; Hauptman, J.; Boldrin, M.N.; Sjörström, L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A Randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients. *Diabetes Care* **2004**, *27*, 155–161. [[CrossRef](#)] [[PubMed](#)]
23. Siebenhofer, A.; Jeitler, K.; Horvath, K.; Berghold, A.; Posch, N.; Meschik, J.; Semlitsch, T. Long-Term Effects of Weight-Reducing Drugs in People with Hypertension. *Cochrane Database Syst. Rev.* **2016**, *3*, CD007654. [[CrossRef](#)]
24. Reitsma, J.B.; Castro Cabezas, M.; de Bruin, T.W.; Erkelens, D.W. Relationship between Improved Postprandial Lipemia and Low-Density Lipoprotein Metabolism during Treatment with Tetrahydropipstatin, a Pancreatic Lipase Inhibitor. *Metabolism* **1994**, *43*, 293–298. [[CrossRef](#)]

25. Hollander, P.A.; Elbein, S.C.; Hirsch, I.B.; Kelley, D.; McGill, J.; Taylor, T.; Weiss, S.R.; Crockett, S.E.; Kaplan, R.A.; Comstock, J.; et al. Role of Orlistat in the Treatment of Obese Patients with Type 2 Diabetes. A 1-Year Randomized Double-Blind Study. *Diabetes Care* **1998**, *21*, 1288–1294. [[CrossRef](#)]
26. Sall, D.; Wang, J.; Rashkin, M.; Welch, M.; Droege, C.; Schauer, D. Orlistat-Induced Fulminant Hepatic Failure. *Clin. Obes.* **2014**, *4*, 342–347. [[CrossRef](#)]
27. Weir, M.A.; Beyea, M.M.; Gomes, T.; Juurlink, D.N.; Mamdani, M.; Blake, P.G.; Wald, R.; Garg, A.X. Orlistat and Acute Kidney Injury: An Analysis of 953 Patients. *Arch. Intern. Med.* **2011**, *171*, 702–710. [[CrossRef](#)]
28. Padwal, R.; Li, S.K.; Lau, D.C.W. Long-Term Pharmacotherapy for Obesity and Overweight. *Cochrane Database Syst. Rev.* **2004**, CD004094. [[CrossRef](#)]
29. Filippatos, T.D.; Derdemezis, C.S.; Gazi, I.F.; Nakou, E.S.; Mikhailidis, D.P.; Elisaf, M.S. Orlistat-Associated Adverse Effects and Drug Interactions: A Critical Review. *Drug Saf.* **2008**, *31*, 53–65. [[CrossRef](#)] [[PubMed](#)]
30. Fleming, J.W.; McClendon, K.S.; Riche, D.M. New Obesity Agents: Lorcaserin and Phentermine/Topiramate. *Ann. Pharmacother.* **2013**, *47*, 1007–1016. [[CrossRef](#)]
31. Allison, D.B.; Gadde, K.M.; Garvey, W.T.; Peterson, C.A.; Schwiers, M.L.; Najarian, T.; Tam, P.Y.; Troupin, B.; Day, W.W. Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP). *Obes. Silver Spring* **2012**, *20*, 330–342. [[CrossRef](#)] [[PubMed](#)]
32. Gadde, K.M.; Allison, D.B.; Ryan, D.H.; Peterson, C.A.; Troupin, B.; Schwiers, M.L.; Day, W.W. Effects of Low-Dose, Controlled-Release, Phentermine plus Topiramate Combination on Weight and Associated Comorbidities in Overweight and Obese Adults (CONQUER): A Randomised, Placebo-Controlled, Phase 3 Trial. *Lancet* **2011**, *377*, 1341–1352. [[CrossRef](#)]
33. Shin, J.H.; Gadde, K.M. Clinical Utility of Phentermine/Topiramate (Qsymia™) Combination for the Treatment of Obesity. *Diabetes Metab. Syndr. Obes.* **2013**, *6*, 131–139. [[CrossRef](#)]
34. Huecker, M.R.; Smiley, A.; Saadabadi, A. Bupropion. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2021.
35. Hendershot, C.S.; Wardell, J.D.; Samokhvalov, A.V.; Rehm, J. Effects of Naltrexone on Alcohol Self-Administration and Craving: Meta-Analysis of Human Laboratory Studies. *Addict. Biol.* **2016**, *22*, 1515–1527. [[CrossRef](#)]
36. Verpeut, J.L.; Bello, N.T. Drug Safety Evaluation of Naltrexone/Bupropion for the Treatment of Obesity. *Expert Opin. Drug Saf.* **2014**, *13*, 831–841. [[CrossRef](#)]
37. Caixàs, A.; Albert, L.; Capel, I.; Rigla, M. Naltrexone Sustained-Release/Bupropion Sustained-Release for the Management of Obesity: Review of the Data to Date. *Drug Des. Dev. Ther.* **2014**, *8*, 1419–1427. [[CrossRef](#)]
38. Greenway, F.L.; Fujioka, K.; Plodkowski, R.A.; Mudaliar, S.; Guttadauria, M.; Erickson, J.; Kim, D.D.; Dunayevich, E.; COR-I Study Group. Effect of Naltrexone plus Bupropion on Weight Loss in Overweight and Obese Adults (COR-I): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. *Lancet* **2010**, *376*, 595–605. [[CrossRef](#)]
39. Christou, G.; Kiortsis, D. The Efficacy and Safety of the Naltrexone/Bupropion Combination for the Treatment of Obesity: An Update. *Hormones* **2015**. [[CrossRef](#)]
40. Nauck, M.A.; Meier, J.J. Incretin Hormones: Their Role in Health and Disease. *Diabetes Obes. Metab.* **2018**, *20* (Suppl. 1), 5–21. [[CrossRef](#)] [[PubMed](#)]
41. Knudsen, L.B.; Lau, J. The Discovery and Development of Liraglutide and Semaglutide. *Front. Endocrinol.* **2019**, *10*, 155. [[CrossRef](#)]
42. Flint, A.; Raben, A.; Astrup, A.; Holst, J.J. Glucagon-like Peptide 1 Promotes Satiety and Suppresses Energy Intake in Humans. *J. Clin. Investig.* **1998**, *101*, 515–520. [[CrossRef](#)]
43. Valassi, E.; Scacchi, M.; Cavagnini, F. Neuroendocrine Control of Food Intake. *Nutr. Metab. Cardiovasc. Dis.* **2008**, *18*, 158–168. [[CrossRef](#)]
44. Davies, M.J.; Bergenstal, R.; Bode, B.; Kushner, R.F.; Lewin, A.; Skjøth, T.V.; Andreasen, A.H.; Jensen, C.B.; DeFronzo, R.A.; NN8022-1922 Study Group. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. *JAMA* **2015**, *314*, 687–699. [[CrossRef](#)]
45. Ladenheim, E.E. Liraglutide and Obesity: A Review of the Data so Far. *Drug Des. Dev. Ther.* **2015**, *9*, 1867–1875. [[CrossRef](#)]
46. Jackson, S.H.; Martin, T.S.; Jones, J.D.; Seal, D.; Emanuel, F. Liraglutide (Victoza): The First Once-Daily Incretin Mimetic Injection for Type-2 Diabetes. *Pharm. Ther.* **2010**, *35*, 498–529.
47. le Roux, C.W.; Astrup, A.; Fujioka, K.; Greenway, F.; Lau, D.C.W.; Van Gaal, L.; Ortiz, R.V.; Wilding, J.P.H.; Skjøth, T.V.; Manning, L.S.; et al. 3 Years of Liraglutide versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals with Prediabetes: A Randomised, Double-Blind Trial. *Lancet* **2017**, *389*, 1399–1409. [[CrossRef](#)]
48. Brunton, S.A.; Mosenzon, O.; Wright, E.E. Integrating Oral Semaglutide into Clinical Practice in Primary Care: For Whom, When, and How? *Postgrad. Med.* **2020**, *132* (Suppl. 2), 48–60. [[CrossRef](#)]
49. O’Neil, P.M.; Birkenfeld, A.L.; McGowan, B.; Mosenzon, O.; Pedersen, S.D.; Wharton, S.; Carson, C.G.; Jepsen, C.H.; Kabisch, M.; Wilding, J.P.H. Efficacy and Safety of Semaglutide Compared with Liraglutide and Placebo for Weight Loss in Patients with Obesity: A Randomised, Double-Blind, Placebo and Active Controlled, Dose-Ranging, Phase 2 Trial. *Lancet* **2018**, *392*, 637–649. [[CrossRef](#)]
50. Aroda, V.R.; Rosenstock, J.; Terauchi, Y.; Altuntas, Y.; Lalic, N.M.; Morales Villegas, E.C.; Jeppesen, O.K.; Christiansen, E.; Hertz, C.L.; Haluzik, M.; et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. *Diabetes Care* **2019**, *42*, 1724–1732. [[CrossRef](#)]

51. Zinman, B.; Aroda, V.R.; Buse, J.B.; Cariou, B.; Harris, S.B.; Hoff, S.T.; Pedersen, K.B.; Tarp-Johansen, M.J.; Araki, E.; PIONEER 8 Investigators. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. *Diabetes Care* **2019**, *42*, 2262–2271. [[CrossRef](#)]
52. Rodbard, H.W.; Rosenstock, J.; Canani, L.H.; Deerochanawong, C.; Gumprecht, J.; Lindberg, S.Ø.; Lingvay, I.; Søndergaard, A.L.; Treppendahl, M.B.; Montanya, E.; et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. *Diabetes Care* **2019**, *42*, 2272–2281. [[CrossRef](#)] [[PubMed](#)]
53. Rosenstock, J.; Allison, D.; Birkenfeld, A.L.; Blicher, T.M.; Deenadayalan, S.; Jacobsen, J.B.; Serusclat, P.; Violante, R.; Watada, H.; Davies, M.; et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. *JAMA* **2019**, *321*, 1466–1480. [[CrossRef](#)] [[PubMed](#)]
54. Pieber, T.R.; Bode, B.; Mertens, A.; Cho, Y.M.; Christiansen, E.; Hertz, C.L.; Wallenstein, S.O.R.; Buse, J.B.; PIONEER 7 Investigators. Efficacy and Safety of Oral Semaglutide with Flexible Dose Adjustment versus Sitagliptin in Type 2 Diabetes (PIONEER 7): A Multicentre, Open-Label, Randomised, Phase 3a Trial. *Lancet Diabetes Endocrinol.* **2019**, *7*, 528–539. [[CrossRef](#)]
55. Pratley, R.; Amod, A.; Hoff, S.T.; Kadowaki, T.; Lingvay, I.; Nauck, M.; Pedersen, K.B.; Saugstrup, T.; Meier, J.J.; PIONEER 4 Investigators. Oral Semaglutide versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4): A Randomised, Double-Blind, Phase 3a Trial. *Lancet* **2019**, *394*, 39–50. [[CrossRef](#)]
56. Baggio, L.L.; Drucker, D.J. Biology of Incretins: GLP-1 and GIP. *Gastroenterology* **2007**, *132*, 2131–2157. [[CrossRef](#)] [[PubMed](#)]
57. Nauck, M.A.; Meier, J.J. The Incretin Effect in Healthy Individuals and Those with Type 2 Diabetes: Physiology, Pathophysiology, and Response to Therapeutic Interventions. *Lancet Diabetes Endocrinol.* **2016**, *4*, 525–536. [[CrossRef](#)]
58. Usdin, T.B.; Mezey, E.; Button, D.C.; Brownstein, M.J.; Bonner, T.I. Gastric Inhibitory Polypeptide Receptor, a Member of the Secretin-Vasoactive Intestinal Peptide Receptor Family, Is Widely Distributed in Peripheral Organs and the Brain. *Endocrinology* **1993**, *133*, 2861–2870. [[CrossRef](#)] [[PubMed](#)]
59. Thornberry, N.A.; Gallwitz, B. Mechanism of Action of Inhibitors of Dipeptidyl-Peptidase-4 (DPP-4). *Best Pract. Res. Clin. Endocrinol. Metab.* **2009**, *23*, 479–486. [[CrossRef](#)]
60. Holst, J.J. The Incretin System in Healthy Humans: The Role of GIP and GLP-1. *Metabolism* **2019**, *96*, 46–55. [[CrossRef](#)]
61. Willard, F.S.; Douros, J.D.; Gabe, M.B.; Showalter, A.D.; Wainscott, D.B.; Suter, T.M.; Capozzi, M.E.; van der Velden, W.J.; Stutsman, C.; Cardona, G.R.; et al. Tirzepatide Is an Imbalanced and Biased Dual GIP and GLP-1 Receptor Agonist. *JCI Insight* **2020**, *5*, 140532. [[CrossRef](#)]
62. Frias, J.P.; Nauck, M.A.; Van, J.; Benson, C.; Bray, R.; Cui, X.; Milicevic, Z.; Urva, S.; Haupt, A.; Robins, D.A. Efficacy and Tolerability of Tirzepatide, a Dual Glucose-Dependent Insulinotropic Peptide and Glucagon-like Peptide-1 Receptor Agonist in Patients with Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Different Dose-Escalation Regimens. *Diabetes Obes. Metab.* **2020**, *22*, 938–946. [[CrossRef](#)]
63. Frias, J.P.; Nauck, M.A.; Van, J.; Kutner, M.E.; Cui, X.; Benson, C.; Urva, S.; Gimeno, R.E.; Milicevic, Z.; Robins, D.; et al. Efficacy and Safety of LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes: A Randomised, Placebo-Controlled and Active Comparator-Controlled Phase 2 Trial. *Lancet* **2018**, *392*, 2180–2193. [[CrossRef](#)]
64. Coskun, T.; Sloop, K.W.; Loghini, C.; Alsina-Fernandez, J.; Urva, S.; Bokvist, K.B.; Cui, X.; Briere, D.A.; Cabrera, O.; Roell, W.C.; et al. LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus: From Discovery to Clinical Proof of Concept. *Mol. Metab.* **2018**, *18*, 3–14. [[CrossRef](#)] [[PubMed](#)]
65. Min, T.; Bain, S.C. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. *Diabetes Ther. Res. Treat. Educ. Diabetes Relat. Disord.* **2021**, *12*, 143–157. [[CrossRef](#)]
66. “Stunning” Twincretin Beats Semaglutide in Type 2 Diabetes. Available online: <http://www.medscape.com/viewarticle/953825> (accessed on 28 June 2021).
67. Holst, J.J.; Albrechtsen, N.J.W.; Gabe, M.B.N.; Rosenkilde, M.M. Oxyntomodulin: Actions and Role in Diabetes. *Peptides* **2018**, *100*, 48–53. [[CrossRef](#)]
68. Pocai, A. Action and Therapeutic Potential of Oxyntomodulin. *Mol. Metab.* **2014**, *3*, 241–251. [[CrossRef](#)] [[PubMed](#)]
69. Camilleri, M.; Acosta, A. Combination Therapies for Obesity. *Metab. Syndr. Relat. Disord.* **2018**, *16*, 390–394. [[CrossRef](#)]
70. Wynne, K.; Park, A.J.; Small, C.J.; Meeran, K.; Ghatei, M.A.; Frost, G.S.; Bloom, S.R. Oxyntomodulin Increases Energy Expenditure in Addition to Decreasing Energy Intake in Overweight and Obese Humans: A Randomised Controlled Trial. *Int. J. Obes.* **2006**, *30*, 1729–1736. [[CrossRef](#)] [[PubMed](#)]
71. Wynne, K.; Park, A.J.; Small, C.J.; Patterson, M.; Ellis, S.M.; Murphy, K.G.; Wren, A.M.; Frost, G.S.; Meeran, K.; Ghatei, M.A.; et al. Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects: A Double-Blind, Randomized, Controlled Trial. *Diabetes* **2005**, *54*, 2390–2395. [[CrossRef](#)] [[PubMed](#)]
72. Scott, R.; Minnion, J.; Tan, T.; Bloom, S.R. Oxyntomodulin Analogue Increases Energy Expenditure via the Glucagon Receptor. *Peptides* **2018**, *104*, 70–77. [[CrossRef](#)]
73. Shankar, S.S.; Shankar, R.R.; Mixson, L.A.; Miller, D.L.; Pramanik, B.; O’Dowd, A.K.; Williams, D.M.; Frederick, C.B.; Beals, C.R.; Stoch, S.A.; et al. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes. *Diabetes* **2018**, *67*, 1105–1112. [[CrossRef](#)]

74. Elvert, R.; Bossart, M.; Herling, A.W.; Weiss, T.; Zhang, B.; Kannt, A.; Wagner, M.; Haack, T.; Evers, A.; Dudda, A.; et al. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys. *Endocrinology* **2018**, *159*, 3105–3119. [[CrossRef](#)]
75. Elashoff, M.; Matveyenko, A.V.; Gier, B.; Elashoff, R.; Butler, P.C. Pancreatitis, Pancreatic, and Thyroid Cancer with Glucagon-like Peptide-1-Based Therapies. *Gastroenterology* **2011**, *141*, 150–156. [[CrossRef](#)] [[PubMed](#)]
76. Grieve, D.J.; Cassidy, R.S.; Green, B.D. Emerging Cardiovascular Actions of the Incretin Hormone Glucagon-like Peptide-1: Potential Therapeutic Benefits beyond Glycaemic Control? *Br. J. Pharmacol.* **2009**, *157*, 1340–1351. [[CrossRef](#)] [[PubMed](#)]
77. Nauck, M.; Frid, A.; Hermansen, K.; Shah, N.S.; Tankova, T.; Mitha, I.H.; Zdravkovic, M.; Düring, M.; Matthews, D.R.; LEAD-2 Study Group. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination with Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 Study. *Diabetes Care* **2009**, *32*, 84–90. [[CrossRef](#)] [[PubMed](#)]
78. Parker, V.E.R.; Robertson, D.; Wang, T.; Hornigold, D.C.; Petrone, M.; Cooper, A.T.; Posch, M.G.; Heise, T.; Plum-Moerschel, L.; Schlichthaar, H.; et al. Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist. *J. Clin. Endocrinol. Metab.* **2020**, *105*, dgz047. [[CrossRef](#)] [[PubMed](#)]
79. Bonora, B.M.; Avogaro, A.; Fadini, G.P. Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. *Diabetes Metab. Syndr. Obes. Targets Ther.* **2020**, *13*, 161–174. [[CrossRef](#)]
80. Clar, C.; Gill, J.A.; Court, R.; Waugh, N. Systematic Review of SGLT2 Receptor Inhibitors in Dual or Triple Therapy in Type 2 Diabetes. *BMJ Open* **2012**, *2*, e001007. [[CrossRef](#)]
81. Bolinder, J.; Ljunggren, Ö.; Kullberg, J.; Johansson, L.; Wilding, J.; Langkilde, A.M.; Sugg, J.; Parikh, S. Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin. *J. Clin. Endocrinol. Metab.* **2012**, *97*, 1020–1031. [[CrossRef](#)]
82. Yokote, K.; Sano, M.; Tsumiyama, I.; Keefe, D. Dose-Dependent Reduction in Body Weight with LIK066 (Licogliflozin) Treatment in Japanese Patients with Obesity. *Diabetes Obes. Metab.* **2020**, *22*, 1102–1110. [[CrossRef](#)] [[PubMed](#)]
83. Lundkvist, P.; Sjöström, C.D.; Amini, S.; Pereira, M.J.; Johnsson, E.; Eriksson, J.W. Dapagliflozin Once-Daily and Exenatide Once-Weekly Dual Therapy: A 24-Week Randomized, Placebo-Controlled, Phase II Study Examining Effects on Body Weight and Prediabetes in Obese Adults without Diabetes. *Diabetes Obes. Metab.* **2017**, *19*, 49–60. [[CrossRef](#)] [[PubMed](#)]
84. Lundkvist, P.; Pereira, M.J.; Katsogiannos, P.; Sjöström, C.D.; Johnsson, E.; Eriksson, J.W. Dapagliflozin Once Daily plus Exenatide Once Weekly in Obese Adults without Diabetes: Sustained Reductions in Body Weight, Glycaemia and Blood Pressure over 1 Year. *Diabetes Obes. Metab.* **2017**, *19*, 1276–1288. [[CrossRef](#)]
85. Anderson, S.L. Dapagliflozin Efficacy and Safety: A Perspective Review. *Ther. Adv. Drug Saf.* **2014**, *5*, 242–254. [[CrossRef](#)]
86. Frías, J.P.; Guja, C.; Hardy, E.; Ahmed, A.; Dong, F.; Öhman, P.; Jabbour, S.A. Exenatide Once Weekly plus Dapagliflozin Once Daily versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy (DURATION-8): A 28 Week, Multicentre, Double-Blind, Phase 3, Randomised Controlled Trial. *Lancet Diabetes Endocrinol.* **2016**, *4*, 1004–1016. [[CrossRef](#)]
87. Fulcher, G.; Matthews, D.R.; Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Mathieu, C.; Woo, V.; Wysham, C.; Capuano, G.; Desai, M.; et al. Efficacy and Safety of Canagliflozin When Used in Conjunction with Incretin-Mimetic Therapy in Patients with Type 2 Diabetes. *Diabetes Obes. Metab.* **2016**, *18*, 82–91. [[CrossRef](#)]
88. Becerril, S.; Frühbeck, G. Cagrilintide plus Semaglutide for Obesity Management. *Lancet* **2021**, *397*, 1687–1689. [[CrossRef](#)]
89. Hartter, E.; Svoboda, T.; Ludvik, B.; Schuller, M.; Lell, B.; Kuenburg, E.; Brunnbauer, M.; Woloszczuk, W.; Prager, R. Basal and Stimulated Plasma Levels of Pancreatic Amylin Indicate Its Co-Secretion with Insulin in Humans. *Diabetologia* **1991**, *34*, 52–54. [[CrossRef](#)]
90. Li, Z.; Kelly, L.; Heiman, M.; Greengard, P.; Friedman, J.M. Hypothalamic Amylin Acts in Concert with Leptin to Regulate Food Intake. *Cell Metab.* **2015**, *22*, 1059–1067. [[CrossRef](#)] [[PubMed](#)]
91. Enebo, L.B.; Berthelsen, K.K.; Kankam, M.; Lund, M.T.; Rubino, D.M.; Satyrganova, A.; Lau, D.C.W. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Concomitant Administration of Multiple Doses of Cagrilintide with Semaglutide 2.4 Mg for Weight Management: A Randomised, Controlled, Phase 1b Trial. *Lancet* **2021**, *397*, 1736–1748. [[CrossRef](#)]
92. Jall, S.; Sachs, S.; Clemmensen, C.; Finan, B.; Neff, F.; DiMarchi, R.D.; Tschöp, M.H.; Müller, T.D.; Hofmann, S.M. Monomeric GLP-1/GIP/Glucagon Triagonism Corrects Obesity, Hepatosteatosis, and Dyslipidemia in Female Mice. *Mol. Metab.* **2017**, *6*, 440–446. [[CrossRef](#)] [[PubMed](#)]
93. Finan, B.; Yang, B.; Ottaway, N.; Smiley, D.L.; Ma, T.; Clemmensen, C.; Chabenne, J.; Zhang, L.; Habegger, K.M.; Fischer, K.; et al. A Rationally Designed Monomeric Peptide Triagonist Corrects Obesity and Diabetes in Rodents. *Nat. Med.* **2015**, *21*, 27–36. [[CrossRef](#)]
94. Kannt, A.; Madsen, A.N.; Kammermeier, C.; Elvert, R.; Klöckener, T.; Bossart, M.; Haack, T.; Evers, A.; Lorenz, K.; Hennerici, W.; et al. Incretin Combination Therapy for the Treatment of Non-Alcoholic Steatohepatitis. *Diabetes Obes. Metab.* **2020**, *22*, 1328–1338. [[CrossRef](#)] [[PubMed](#)]
95. Batterham, R.L.; Cowley, M.A.; Small, C.J.; Herzog, H.; Cohen, M.A.; Dakin, C.L.; Wren, A.M.; Brynes, A.E.; Low, M.J.; Ghatei, M.A.; et al. Gut Hormone PYY(3-36) Physiologically Inhibits Food Intake. *Nature* **2002**, *418*, 650–654. [[CrossRef](#)] [[PubMed](#)]

96. Dirksen, C.; Jørgensen, N.B.; Bojsen-Møller, K.N.; Kielgast, U.; Jacobsen, S.H.; Clausen, T.R.; Worm, D.; Hartmann, B.; Rehfeld, J.F.; Damgaard, M.; et al. Gut Hormones, Early Dumping and Resting Energy Expenditure in Patients with Good and Poor Weight Loss Response after Roux-En-Y Gastric Bypass. *Int. J. Obes.* **2013**, *37*, 1452–1459. [[CrossRef](#)]
97. Mingrone, G.; Nolfo, G.; Gissey, G.C.; Iaconelli, A.; Leccesi, L.; Guidone, C.; Nanni, G.; Holst, J.J. Circadian Rhythms of GIP and GLP1 in Glucose-Tolerant and in Type 2 Diabetic Patients after Biliopancreatic Diversion. *Diabetologia* **2009**, *52*, 873–881. [[CrossRef](#)] [[PubMed](#)]
98. Behary, P.; Tharakan, G.; Alexiadou, K.; Johnson, N.; Wewer Albrechtsen, N.J.; Kenkre, J.; Cuenco, J.; Hope, D.; Anyiam, O.; Choudhury, S.; et al. Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. *Diabetes Care* **2019**, *42*, 1446–1453. [[CrossRef](#)] [[PubMed](#)]
99. Schmidt, J.B.; Gregersen, N.T.; Pedersen, S.D.; Arentoft, J.L.; Ritz, C.; Schwartz, T.W.; Holst, J.J.; Astrup, A.; Sjödin, A. Effects of PYY3-36 and GLP-1 on Energy Intake, Energy Expenditure, and Appetite in Overweight Men. *Am. J. Physiol. Endocrinol. Metab.* **2014**, *306*, E1248–E1256. [[CrossRef](#)] [[PubMed](#)]
100. Kaplan, L.M.; Golden, A.; Jinnett, K.; Kolotkin, R.L.; Kyle, T.K.; Look, M.; Nadglowski, J.; O’Neil, P.M.; Parry, T.; Tomaszewski, K.J.; et al. Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study. *Obes. Silver Spring* **2018**, *26*, 61–69. [[CrossRef](#)]
101. Patel, D. Pharmacotherapy for the Management of Obesity. *Metabolism.* **2015**, *64*, 1376–1385. [[CrossRef](#)]
102. Casimiro, I.; Sam, S.; Brady, M.J. Endocrine Implications of Bariatric Surgery: A Review on the Intersection between Incretins, Bone, and Sex Hormones. *Physiol. Rep.* **2019**, *7*, e14111. [[CrossRef](#)]
103. Kassir, R.; Debs, T.; Blanc, P.; Gugenheim, J.; Ben Amor, I.; Boutet, C.; Tiffet, O. Complications of Bariatric Surgery: Presentation and Emergency Management. *Int. J. Surg. Lond. Engl.* **2016**, *27*, 77–81. [[CrossRef](#)]
104. Gribble, F.M.; Reimann, F. Function and Mechanisms of Enteroendocrine Cells and Gut Hormones in Metabolism. *Nat. Rev. Endocrinol.* **2019**, *15*, 226–237. [[CrossRef](#)] [[PubMed](#)]
105. le Roux, C.W.; Welbourn, R.; Werling, M.; Osborne, A.; Kokkinos, A.; Laurenus, A.; Lönroth, H.; Fändriks, L.; Ghatei, M.A.; Bloom, S.R.; et al. Gut Hormones as Mediators of Appetite and Weight Loss after Roux-En-Y Gastric Bypass. *Ann. Surg.* **2007**, *246*, 780–785. [[CrossRef](#)] [[PubMed](#)]